Bausch And Lomb Inc patents expiration
1. Bepreve patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6780877 | BAUSCH AND LOMB INC | Acid addition salt of optically active piperidine compound and process for preparing the same |
Sep, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8877168 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jul, 2023
(8 months ago) | |
| US8784789 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jan, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 08, 2014 |
Drugs and Companies using BEPOTASTINE BESILATE ingredient
NCE-1 date: 08 September, 2013
Market Authorisation Date: 08 September, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
BEPREVE family patents
2. Lotemax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5800807 | BAUSCH AND LOMB INC | Ophthalmic compositions including glycerin and propylene glycol |
Jan, 2017
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-229) | Jul 20, 2021 |
| New Dosage Form(NDF) | Sep 28, 2015 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 28 September, 2012
Treatment: NA
Dosage: GEL;OPHTHALMIC
LOTEMAX family patents
3. Lotemax Sm patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11534395 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Jan, 2036
(11 years from now) | |
| US10596107 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Feb 22, 2022 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 February, 2019
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
Dosage: GEL;OPHTHALMIC
LOTEMAX SM family patents
4. Lumify patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596600 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(5 years from now) | |
| US11833245 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(5 years from now) | |
| US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(6 years from now) | |
| US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2020 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIFY family patents
5. Macugen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6113906 | BAUSCH AND LOMB INC | Water-soluble non-antigenic polymer linkable to biologically active material |
Oct, 2013
(10 years ago) | |
| US5919455 | BAUSCH AND LOMB INC | Non-antigenic branched polymer conjugates |
Oct, 2013
(10 years ago) | |
| US6051698 | BAUSCH AND LOMB INC | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
May, 2015
(8 years ago) | |
| US5932462 | BAUSCH AND LOMB INC | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
Aug, 2016
(7 years ago) | |
| US6011020 | BAUSCH AND LOMB INC | Nucleic acid ligand complexes |
Jan, 2017
(7 years ago) | |
Drugs and Companies using PEGAPTANIB SODIUM ingredient
Market Authorisation Date: 17 December, 2004
Treatment: Treatment of vegf mediated ocular disease.
Dosage: INJECTABLE;INTRAVITREAL
MACUGEN family patents
6. Miebo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10369117 | BAUSCH AND LOMB INC | Compositions comprising mixtures of semifluorinated alkanes |
Sep, 2033
(9 years from now) | |
| US10449164 | BAUSCH AND LOMB INC | Methods of treating ocular disorders using semifluorinated alkanes |
Sep, 2033
(9 years from now) | |
| US10058615 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(9 years from now) | |
| US10576154 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(9 years from now) | |
| US11357738 | BAUSCH AND LOMB INC | Semifluorinated compounds and their compositions |
Sep, 2036
(12 years from now) | |
| US10507132 | BAUSCH AND LOMB INC | Topical administration method |
Jun, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
MIEBO family patents
7. Xipere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8636713 | BAUSCH AND LOMB INC | Methods and devices for drug delivery to ocular tissue using microneedle |
May, 2027
(3 years from now) | |
| US9636332 | BAUSCH AND LOMB INC | Methods and devices for the treatment of ocular diseases in human subjects |
Nov, 2033
(9 years from now) | |
| US9937075 | BAUSCH AND LOMB INC | Apparatus and methods for ocular injection |
May, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2024 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 22 October, 2021
Treatment: Treatment of macular edema associated with uveitis
Dosage: SUSPENSION;INJECTION
XIPERE family patents